BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report) shares traded down 2% during trading on Wednesday . The company traded as low as C$4.93 and last traded at C$4.95. Approximately 6,796 shares were traded during mid-day trading, a decline of 60% from the average session volume of 17,127 shares. The stock had previously closed at C$5.05.
BriaCell Therapeutics Price Performance
The firm has a 50-day moving average of C$5.00 and a two-hundred day moving average of C$5.15. The company has a market capitalization of C$42.37 million, a PE ratio of -5.80 and a beta of 2.26.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to developing novel immunotherapies to fight cancer and improve patients’ lives. Immunotherapies have become the forefront of the fight against cancer because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Defense Stocks Are Pulling Back as Their Navy Tailwinds Get Stronger
- Survey Reveals: America’s Top Autumn Activities that are Free [2026]
- Defying Gravity: Space Stocks Reach Escape Velocity
- Credo Technology Just Plunged 20%—Did the Market Overreact?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
